Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has been postmenopausal for 3 years~* Participant has BMD t-score at the total hip, hip trochanter, femoral neck, or lumbar spine ≥ -1.5 but \> -3.5~* Participant has 2 hips that are evaluable by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), e.g. contain no hardware from orthopedic procedures~* Participant is ambulatory~Exclusion Criteria:~* Participant has had a previous hip fracture~* Participant has had \>1 prior clinical vertebral fracture AND is a candidate for osteoporosis therapy~* Participant has been treated with oral bisphosphonates, strontium, parathyroid hormone (PTH) or other agents with an effect on bone~* Participant has had metabolic bone disorder other than osteoporosis~* Participant has renal stones, Parkinson's disease, multiple sclerosis (MS) or active parathyroid disease.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Odanacatib 50 mg (Type: EXPERIMENTAL): Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).